Treatment results and outcome in elderly patients with glioblastoma multiforme - A retrospective single institution analysis

被引:31
作者
Hoffermann, Markus [1 ]
Bruckmann, Lukas [1 ]
Ali, Kariem Mandy [1 ]
Asslaber, Martin [2 ]
Payer, Franz [3 ]
von Campe, Gord [1 ]
机构
[1] Med Univ Graz, Dept Neurosurg, A-8036 Graz, Austria
[2] Med Univ Graz, Inst Pathol, A-8036 Graz, Austria
[3] Med Univ Graz, Dept Neurol, A-8036 Graz, Austria
关键词
Elderly; Extent of resection; Glioblastoma; Malignant Primary Brain Tumors; Temozolomide; HIGH-GRADE GLIOMAS; NEWLY-DIAGNOSED GLIOBLASTOMA; SURVIVAL CLINICAL ARTICLE; QUALITY-OF-LIFE; RADIOTHERAPY PLUS CONCOMITANT; GROSS-TOTAL RESECTION; ADJUVANT TEMOZOLOMIDE; RADIATION-THERAPY; PROGNOSTIC-FACTORS; MALIGNANT GLIOMAS;
D O I
10.1016/j.clineuro.2014.11.006
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Although glioblastoma multiforme is more common in patients older than 65 years, the elderly population is often excluded from clinical studies. Decision making in this subgroup can be challenging due to the lack of evidence for different neurosurgical and adjuvant treatment strategies. Methods: In this retrospective study, we evaluated clinical, treatment and survival data of 124 consecutive patients over 65 years of age with supratentorial glioblastoma multiforme. Results: Median OS was 6.0 months (std. error 0.783, 95% CI 4.456-7.535). Mean OS was 9.7 months (std. error 0.830,95% CI 8.073-11.327). In univariate regression analysis, low KPS was of negative prognostic value (p<0.006 for KPS <= 80), while greater advanced age did not have any impact on survival (p = 0.591 for differences between groups). Gross total resection and subtotal resection led to significantly improved overall survival (median 15.0 and 11.0 months: p<0.02) compared to partial resection or biopsy (both 4.0 months), but complications were more common in subtotal and partial resections. The last observation did not reach statistical significance (p = 0.06). Combinations of irradiation and Temozolomide chemotherapy proved to be more effective than other adjuvant therapies. Extent of resection (gross total resection vs. all others) and form of adjuvant treatment were the only factors of independent prognostic value in multivariate analysis (p = 0.031 and p<0.001, respectively). Conclusions: It appears that more aggressive treatment regimens can lead to longer overall survival in elderly glioblastoma multiforme patients. Gross total resection should be offered whenever safely possible; otherwise, biopsy may be preferred. Non-surgical treatment should consist of postoperative radiotherapy and concomitant and/or adjuvant chemotherapy. Possibly higher rates of hematological side effects in concomitant chemotherapy need to be further investigated. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:60 / 69
页数:10
相关论文
共 95 条
[51]  
NITTA T, 1995, CANCER-AM CANCER SOC, V75, P2727, DOI 10.1002/1097-0142(19950601)75:11<2727::AID-CNCR2820751115>3.0.CO
[52]  
2-H
[53]   Epidemiology and etiology of gliomas [J].
Ohgaki, H ;
Kleihues, P .
ACTA NEUROPATHOLOGICA, 2005, 109 (01) :93-108
[54]   Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival Clinical article [J].
Orringer, Daniel ;
Lau, Darryl ;
Khatri, Sameer ;
Zamora-Berridi, Grettel J. ;
Zhang, Kathy ;
Wu, Chris ;
Chaudhary, Neeraj ;
Sagher, Oren .
JOURNAL OF NEUROSURGERY, 2012, 117 (05) :851-859
[55]   Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age [J].
Oszvald, Agi ;
Gueresir, Erdem ;
Setzer, Matthias ;
Vatter, Hartmut ;
Senft, Christian ;
Seifert, Volker ;
Franz, Kea .
JOURNAL OF NEUROSURGERY, 2012, 116 (02) :357-364
[56]   Survival trends in elderly patients with glioblastoma multiforme: Resective surgery, radiation, and chemotherapy [J].
Patwardhan, RV ;
Shorter, C ;
Willis, BK ;
Reddy, P ;
Smith, D ;
Caldito, GC ;
Nanda, A .
SURGICAL NEUROLOGY, 2004, 62 (03) :207-215
[57]   Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial [J].
Perez-Larraya, Jaime Gallego ;
Ducray, Francois ;
Chinot, Olivier ;
Catry-Thomas, Isabelle ;
Taillandier, Luc ;
Guillamo, Jean-Sebastien ;
Campello, Chantal ;
Monjour, Annick ;
Cartalat-Carel, Stephanie ;
Barrie, Maryline ;
Huchet, Aymeri ;
Beauchesne, Patrick ;
Matta, Mona ;
Mokhtari, Karima ;
Tanguy, Marie-Laure ;
Honnorat, Jerome ;
Delattre, Jean-Yves .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (22) :3050-3055
[58]   EVALUATION OF BROMODEOXYURIDINE IN GLIOBLASTOMA-MULTIFORME - A NORTHERN CALIFORNIA CANCER CENTER PHASE-II STUDY [J].
PHILLIPS, TL ;
LEVIN, VA ;
AHN, DK ;
GUTIN, PH ;
DAVIS, RL ;
WILSON, CB ;
PRADOS, MD ;
WARA, WM ;
FLAM, MS .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 21 (03) :709-714
[59]  
Pope WB, 2005, AM J NEURORADIOL, V26, P2466
[60]   HIGHLY ANAPLASTIC ASTROCYTOMA - A REVIEW OF 357 PATIENTS TREATED BETWEEN 1977 AND 1989 [J].
PRADOS, MD ;
GUTIN, PH ;
PHILLIPS, TL ;
WARA, WM ;
LARSON, DA ;
SNEED, PK ;
DAVIS, RL ;
AHN, DK ;
LAMBORN, K ;
WILSON, CB .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 23 (01) :3-8